Skip to main content
Premium Trial:

Request an Annual Quote

And Adolescents

Pfizer and BioNTech have announced that their SARS-CoV-2 vaccine is highly effective at preventing COVID-19 in adolescents, NPR reports.

In a statement, the companies say in their Phase 3 trial of 2,260 individuals between the ages of 12 and 15, their vaccine exhibited 100 percent efficacy in preventing COVID-19. During the trial, 18 individuals — all in the placebo group — developed COVID-19.

Pfizer CEO Albert Bourla says they plan to submit this additional data to the US Food and Drug Administration to amend their current Emergency Use Authorization to include this age group with the hope of enabling vaccinations before the start of the next school year. "It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones," Ugur Sahin, CEO and co-founder of BioNTech, adds in a statement.

NPR notes that Pfizer and BioNTech are further testing their vaccine in even younger children and that Moderna and Johnson & Johnson are also conducting clinical trials of their vaccines in children and adolescents.